RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Keep patient, maybe we are at last step to the final victoryMatthew Perraton, PFP, FMA, FCSI, Pro. Dir., Chairman of the Board of Theralase®, stated, "We are thrilled to welcome an individual of this caliber to our Board. Dr. Lbiati possesses a wealth of international experience across all aspects of drug development, from: clinical research to medical affairs, marketing to commercialization of various drug candidates. Her expertise comes at an opportune time, as we have made great strides in our Phase II BCG-Unresponsive NMIBC clinical study ("Study II"), whose strong interim clinical data verifies that light-activated Ruvidar™ is a potent Photo Dynamic Compound ("PDC") that is capable of destroying high-grade bladder cancer and providing a durable response to this disease, while providing a very high safety profile for the treated patient. Based on this latest interim clinical data, the Company is commencing to actively explore international partnering, licensing and distribution opportunities for our cancer targeting PDC, Ruvidar™."
Bhavya Bajantri M.Sc., CCRP and Sonia Keshwani B.Sc., CCRP